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Abstract The observed biological differences in
safety and efficacy of intravenous (IV) iron formula-
tions are attributable to physicochemical differences.
In addition to differences in carbohydrate shell,
polarographic signatures due to ferric iron [Fe(III)]
and ferrous iron [Fe(II)] differ among IV iron formu-
lations. Intravenous iron contains Fe(II) and releases
labile iron in the circulation. Fe(II) generates toxic free
radicals and reactive oxygen species and binds to
bacterial siderophores and other in vivo sequestering
agents. To evaluate whether differences in Fe(II)
content may account for some observed biological
differences between IV iron formulations, samples
from multiple lots of various IV iron formulations
were dissolved in 12 M concentrated HCl to dissociate
and release all iron and then diluted with water to
achieve 0.1 M HCl concentration. Fe(II) was then
directly measured using ferrozine reagent and ultravi-
olet spectroscopy at 562 nm. Total iron content was
measured by adding an excess of ascorbic acid to
reduce Fe(III) to Fe(II), and Fe(II) was then measured
by ferrozine assay. The Fe(II) concentration as a
proportion of total iron content [Fe(III) ? Fe(II)] in
different lots of IV iron formulations was as follows:
iron gluconate, 1.4 and 1.8 %; ferumoxytol, 0.26 %;
ferric carboxymaltose, 1.4 %; iron dextran, 0.8 %; and
iron sucrose, 10.2, 15.5, and 11.0 % (average,
12.2 %). The average Fe(II) content in iron sucrose
was, therefore, C7.5-fold higher than in the other IV
iron formulations. Further studies are needed to
investigate the relationship between Fe(II) content
and increased risk of oxidative stress and infections
with iron sucrose.
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Introduction
All formulations of iron suitable for intravenous (IV)
administration are colloidal suspensions of iron oxide
nanoparticles, with particle size ranging from 5 to
40 nm. These nanoparticles are composed of a
polynuclear iron-oxyhydroxide/oxide central core
surrounded by a carbohydrate shell, which stabilizes
the core and protects the nanoparticles against further
polymerization (Neiser et al. 2015). Different IV iron
formulations have distinct properties and display a
wide range of stability, degradation kinetics in the
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circulation, and antigenic potential, depending on the
type of stabilizing carbohydrate (Geisser and Burck-
hardt 2011).
The core particle size has an influence on iron
lability: the smaller the size, the greater the surface
area-to-volume ratio and, therefore, the greater the
lability of bound iron. This is due to the physical
dissociation of iron from the particle surface. The
electrovalence of iron also influences iron lability.
Ferrous iron [Fe(II)] is kinetically more reactive
(labile) than ferric iron [Fe(III)] with respect to
exchanging its nearest neighbor bonding atoms (li-
gands) (Helm and Merbach 2005). This means that
dissociation from the nano-particle surface is more
facile for Fe(II). However, this also means that its
reaction with potential in vivo binding sites is less
discriminating, thus making delivery to the desired
transferrin site less probable or at least delayed. Fe(II)
can readily bind to bacterial siderophores, potentially
leading to infection (Farkas et al. 2001). In addition
Fe(II) can readily undergo redox reactions with
metabolites, such as peroxides, to generate highly
toxic reactive oxygen species, which cause oxidative
stress and damage to cellular constituents (Crichton
and Boelaert 2001; Geisser and Burckhardt 2011).
It has become increasingly recognized that the size
and variability of the iron core and the types of
impurities that are present (e.g., the ratio of divalent
and trivalent iron) are among the quality attributes of
IV iron formulations that impact efficacy and safety
(European Medicines Agency 2013). Therefore, we
performed comparative analyses of the Fe(II) content
of different formulations of IV iron that are available
for commercial use in the United States.
Methods
Commercially available IV iron formulations were
obtained and assayed for Fe(II) and total iron B5 min
after the vials were opened. All measurements of
Fe(II) and total iron were performed in quadruplicate,
taking samples from the dilute iron solution.
Fe(II) iron content
A 100 lL volume of sample was mixed with 1 mL of
12 M concentrated HCl (37 % HCl by weight) to
produce clear yellow solutions (1/11 dilution) of each
IV iron formulation. A 100 lL volume of the (1/11)
dilution was mixed with 10 mL of H2O to achieve a
1/1100 dilution (0.1 M HCl concentration). A 200 lL
volume of 1/1100 dilution was mixed with 50 lL of
0.7 M sodium acetate to adjust the pH to 4.0 after
which 20 lL of 1 mg/mL ferrozine was added. After a
5-min incubation, this solution was scanned on the
ultraviolet (UV) plate reader to determine the ampli-
tude of the peak at 562 nm wavelength. Fe(II) content
was determined by reference to a 5 lM standard. The
concentration of the Fe(II) in the initial sample was
calculated, after adjustment for dilutions, and reported
as the percent of total iron. The percent of total iron
was compared to the label value for each of the IV iron
preparations.
Total iron content
The 1/1100 dilution was further diluted to a final HCl
concentration of 0.1 M. A 100 lL volume was mixed
with 1.9 mL of 12 M HCl to achieve a 1/22,000
dilution. A 200 lL volume of the 1/22,000 dilution
was mixed with 20 lL of 10 mg/mL ascorbic acid to
convert all iron to Fe(II). After adjusting the pH to 4.0
with 50 lL of sodium acetate, 20 lL of ferrozine was
added. The 562 nm peak was determined after a 5-min
incubation, and the total iron content of the sample
was calculated by reference to the Fe(II) iron standard.
Results
The Fe(II) content was measured in single lots of iron
dextran (INFeDTM), ferumoxytol (FerahemeTM), and
ferric carboxymaltose (InjectaferTM); 2 lots of iron
gluconate (FerrlecitTM); and 3 lots of iron sucrose
(VenoferTM) (Table 1). As a fraction of the measured
total iron, the measured Fe(II) content was\1 % for
iron dextran and ferumoxytol, 1–2 % for ferric
carboxymaltose and iron gluconate, and 10–15 % for
iron sucrose. The Fe(II) content in iron sucrose was
C7.5-fold higher than in any of the other IV iron
formulations.
Discussion
The differences in Fe(II) content between the various
IV iron formulations that we observed are consistent
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with the differences in polarographic signatures due to
the Fe(III)/Fe(II) couple between the different IV
formulations (Neiser et al. 2015). In this study, we
found that the Fe(II) content in iron sucrose (Veno-
ferTM), the most commonly used IV iron formulation
in hemodialysis patients in the United States, was
significantly higher than that in the other IV formu-
lations that we evaluated.
Intravenous iron formulations release 2–6 % of
their total iron into the circulation whereas the
majority of iron undergoes uptake by the reticuloen-
dothelial macrophages in liver, spleen, lymph nodes,
and bone marrow (Beshara et al. 1999). An increase in
Fe(II) in the circulation with iron sucrose would be
expected to enhance generation of free radicals and
oxidant stress relative to other IV iron formulations.
Stefansson et al. (2011) measured plasma iron and
oxidative stress parameters before and 10 min after IV
injection of 100 mg iron sucrose or iron dextran in
20 chronic hemodialysis patients and found that non-
transferrin-bound iron increased significantly more
after administration of iron sucrose than after admin-
istration of iron dextran (86 ± 42 vs 45 ± 45 %,
respectively; P\ 0.05). Furthermore, plasma ascorbic
free radical did not change after administration of iron
dextran (-1.8 ± 11.2 %) but increased by 29 ±
31.3 % after administration of iron sucrose
(P\ 0.01). Additionally, protein carbonyls increased
after administration of iron sucrose (P\ 0.05) but not
after administration of iron dextran.Wang et al. (2008)
demonstrated increased oxidation of ascorbic acid in
human plasma and whole blood with iron sucrose
relative to iron gluconate. All 3 biomarkers (non-
transferrin-bound iron, protein carbonyl, and ascor-
bate radical levels) suggest a higher level of oxidative
stress associated with iron sucrose administration.
Release of non-transferrin bound iron following
treatment of hemodialysis patients with iron sucrose
has also been associated with enhanced growth of
Staphylococcus aureus after inoculation into serum
samples from these patients (Barton Pai et al. 2006).
Iron sucrose also has specific immunologic effects on
Table 1 Fe(II) and total iron content of intravenous iron formulations















Ferric carboxymaltose (InjectaferTM) 1501901
Feb 2017
1.4 48 50

















a Total iron content was not determined for these lot numbers because analysis of total iron content for the first lot and for the other
iron formulations generated label values
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monocytes and hematopoietic stem cells that were not
induced by the other IV iron preparations (Fell et al.
2014). Iron sucrose activated monocyte subsets lead-
ing to significantly increased CD86 expression.
Simultaneously, CD16 and CX3CR1 expression and
monocytic phagocytosis capacity were decreased.
Additionally, differentiation of monocytes from
hematopoietic CD34? stem cells was almost com-
pletely abolished after stimulation with iron sucrose.
This effect of iron sucrose on immune cells may
contribute to a higher risk of infections observed in
dialysis patients who are treated with iron sucrose
(Brookhart et al. 2016; Sirken et al. 2006).
Our study did not measure Fe(II) after addition of
various iron compounds to plasma or blood or
following administration to patients because divalent
iron is rapidly oxidized in the plasma to Fe(III) by
plasma ceruloplasmin (Roeser et al. 1970). Further-
more, the results of our study should be considered
with caution because we have not studied the fate of
Fe(II) and Fe(III) in the plasma with respect to
transferrin binding or uptake by parenchymal cells and
macrophages. Other studies, as referenced above, have
noted the difference in IV administration of iron
sucrose with respect to infection, immune response,
and oxidative stress. Results presented here suggest
this may be due, at least in part, to high Fe(II) content.
Consequently, the significantly higher Fe(II) content
in iron sucrose (VenoferTM) is a cause for concern
given the toxic nature of this species. Further studies
are needed to investigate the relationship between
Fe(II) content and increased risk of oxidative stress
and infections with iron sucrose.
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